Altered protein expression in serum from endometrial hyperplasia and carcinoma patients

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Wang, Yi Sheng ^a   Cao, Rui ^b   Jin, Hong ^a   Huang, Yi Ping ^a   Zhang, Xiao Yan ^a   Cong, Qing ^a   He, Yi Feng ^a   Xu, Cong Jian ^a  

^a FUDAN UNIVERSITY   (China)

^b Dalian Gynecology and Obstetrics Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANTITHROMBIN III; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; GLYCOPROTEIN; HAPTOGLOBIN; HISTIDINE RICH GLYCOPROTEIN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; OROSOMUCOID; OROSOMUCOID 1; PROTEIN; PROTEIN SERPINC 1; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; ATYPICAL ENDOMETRIAL HYPERPLASIA; BIOINFORMATICS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; COMPLEX ENDOMETRIAL HYPERPLASIA; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC TEST; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; NON INVASIVE MEASUREMENT; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SERUM; SIMPLE ENDOMETRIAL HYPERPLASIA; TANDEM MASS SPECTROMETRY; BLOOD; EARLY DIAGNOSIS; ENDOMETRIUM TUMOR; METHODOLOGY;

CHROMATOGRAPHY, LIQUID; EARLY DETECTION OF CANCER; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PROTEINS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 79953844500     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-15     Document Type: Article

References (37)

1. Current status of gynecological cancer in China. K Kim R Zang SC Choi SY Ryu JW Kim, J Gynecol Oncol 2009 20 72 76 10.3802/jgo.2009.20.2.72 19590717
2. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. G Plataniotis M Castiglione EGW Grp, Annals of Oncology 2010 21 & 2241 v45 10.1093/annonc/mdq245 20555100
3. Ovarian cancer immunotherapy: opportunities, progresses and challenges. B Liu J Nash C Runowicz H Swede R Stevens ZH Li, Journal of Hematology & Oncology 2010 3
4. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. L DeSouza G Diehl MJ Rodrigues J Guo AD Romaschin TJ Colgan KW Siu, J Proteome Res 2005 4 377 386 10.1021/pr049821j 15822913 (Pubitemid 40548142)
5. Identification of Candidate Biomarker Proteins Released by Human Endometrial and Cervical Cancer Cells Using Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry. H Li LV DeSouza S Ghanny W Li AD Romaschin TJ Colgan KWM Siu, J Proteome Res 2007 6 2615 2622 10.1021/pr0700798 17523614 (Pubitemid 47122356)
6. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: Analysis using 2-DE with silver staining and lectin detection methods. PS Abdul-Rahman BK Lim OH Hashim, ELECTROPHORESIS 2007 28 1989 1996 10.1002/elps.200600629 17503403 (Pubitemid 47040404)
7. Protein Expression Profiling of Endometrial Malignancies Reveals a New Tumor Marker: Chaperonin 10. ECC Yang J Guo G Diehl L DeSouza MJ Rodrigues AD Romaschin TJ Colgan KWM Siu, Journal of Proteome Research 2004 3 636 643 10.1021/pr049975z 15253447 (Pubitemid 39207370)
8. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. LV DeSouza J Grigull S Ghanny V Dube AD Romaschin TJ Colgan KW Siu, Mol Cell Proteomics 2007 6 1170 1182 10.1074/mcp.M600378-MCP200 17374602 (Pubitemid 47099227)
9. Serum proteomic features for detection of endometrial cancer. LR Zhu WY Zhang L Yu YH Zheng JZ Zhang QP Liao, Int J Gynecol Cancer 2006 16 1374 1378 10.1111/j.1525-1438.2006.00561.x 16803533 (Pubitemid 43886772)
10. Altered protein expression in endometrial carcinogenesis. T Yoshizaki T Enomoto R Nakashima Y Ueda H Kanao K Yoshino M Fukumoto Y Yoneda GS Buzard Y Murata, Cancer Letters 2005 226 101 106 10.1016/j.canlet.2004.11.053 16039949 (Pubitemid 41039077)
11. Direct analysis of laser capture microdissected endometrial carcinoma and epithelium by matrix-assisted laser desorption/ionization mass spectrometry. J Guo TJ Colgan LV DeSouza MJ Rodrigues AD Romaschin KWM Siu, Rapid Communications in Mass Spectrometry 2005 19 2762 2766 10.1002/rcm.2119 16134212 (Pubitemid 41383358)
12. Two-dimensional gel analysis of human endometrial proteins: characterization of proteins with increased expression in hyperplasia and adenocarcinoma. I Byrjalsen P Mose Larsen SJ Fey L Nilas MR Larsen C Christiansen, Mol Hum Reprod 1999 5 748 756 10.1093/molehr/5.8.748 10421803 (Pubitemid 29366873)
13. Identification of potential serum markers for endometrial cancer using protein expression profiling. M Takano Y Kikuchi T Asakawa T Goto T Kita K Kudoh J Kigawa N Sakuragi M Sakamoto T Sugiyama N Yaegashi H Tsuda H Seto M Shiwa, J Cancer Res Clin Oncol 2010 136 475 481 10.1007/s00432-009-0680-7 19756734
14. Proteomics-Based Approach Identified Differentially Expressed Proteins With Potential Roles in Endometrial Carcinoma. ZY Li WJ Min CH Huang SJ Bai MH Tang X Zhao, Int J Gynecol Cancer 2010 20 9 15 10.1111/IGC.0b013e3181a9026d 20057284
15. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Z Yurkovetsky S Ta'asan S Skates A Rand A Lomakin F Linkov A Marrangoni L Velikokhatnaya M Winans E Gorelik GL Maxwell K Lu A Lokshin, Gynecologic Oncology 2007 107 58 65 10.1016/j.ygyno. 2007.05.041 17659325 (Pubitemid 47464542)
16. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. A Negishi M Ono Y Handa H Kato K Yamashita K Honda M Shitashige R Satow T Sakuma H Kuwabara K Omura S Hirohashi T Yamada, Cancer Sci 2009 100 514 519 10.1111/j.1349-7006.2008.01055.x 19154406
17. Proteomics Identification of Cyclophilin A as a Potential Prognostic Factor and Therapeutic Target in Endometrial Carcinoma. ZY Li X Zhao SJ Bai Z Wang LJ Chen YQ Wei CH Huang, Mol Cell Proteomics 2008 7 1810 1823 10.1074/mcp.M700544-MCP200 18421009
18. A perspective on the use of iTRAQTM reagent technology for protein complex and profiling studies. LR Zieske, J Exp Bot 2006 57 1501 1508 10.1093/jxb/erj168 16574745
19. Identification of serum biomarkers in brain-injured adults: Potential for predicting elevated intracranial pressure. G Hergenroeder JB Redell AN Moore WP Dubinsky RT Funk J Crommett GL Clifton R Levine A Valadka PK Dash, Journal of Neurotrauma 2008 25 79 93 10.1089/neu.2007.0386 18260791 (Pubitemid 351252579)
20. Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. Y Chen BK Lim OH Hashim, Journal of Hematology & Oncology 2009 2 37
21. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. E Mohamed PS Abdul-Rahman SR Doustjaialil Y Chen BK Lim SZ Omar AZ BustaM VA Singh N Mohd-Taib CH Yip OH Hashim, Electrophoresis 2008 29 2645 2650 10.1002/elps.200700828 18494030 (Pubitemid 351911892)
22. Serum amyloid A, the major vertebrate acute-phase reactant. CM Uhlar AS Whitehead, European Journal of Biochemistry 1999 265 501 523 10.1046/j.1432-1327.1999.00657.x 10504381 (Pubitemid 29488982)
23. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. E Malle S Sodin-Semrl A Kovacevic, Cellular and Molecular Life Sciences 2009 66 9 26 10.1007/s00018-008-8321-x 18726069
24. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. O Gutfeld D Prus Z Ackerman S Dishon RP Linke M Levin S Urieli-Shoval, J Histochem Cytochem 2006 54 63 73 10.1369/jhc.5A6645.2005 16116035 (Pubitemid 43049416)
25. Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format. V Dube J Grigull LV DeSouza S Ghanny TJ Colgan AD Romaschin KW Siu, J Proteome Res 2007 6 2648 2655 10.1021/pr070087o 17552551 (Pubitemid 47122360)
26. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. YF Wong TH Cheung KWK Lo SF Yim NSS Siu SCS Chan TWF Ho KWY Wong MY Yu VW Wang C Li GJ Gardner T Bonome WB Johnson DI Smith TKH Chung MJ Birrer, Oncogene 2007 26 1971 1982 10.1038/sj.onc.1209986 17043662 (Pubitemid 46474633)
27. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). N Tsuchida-Straeten S Ensslen C Schafer M Woltje B Denecke M Moser S Graber S Wakabayashi T Koide W Jahnen-Dechent, J Thromb Haemost 2005 3 865 872 10.1111/j.1538-7836.2005.01238.x 15869579 (Pubitemid 41632812)
28. Histidine-rich glycoprotein exerts antibacterial activity. V Rydengard AK Olsson M Morgelin A Schmidtchen, Febs Journal 2007 274 377 389 10.1111/j.1742-4658.2006.05586.x 17229145 (Pubitemid 46046648)
29. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. AK Olsson H Larsson J Dixelius I Johansson C Lee C Oellig I Bjork L Claesson-Welsh, Cancer research 2004 64 599 605 10.1158/0008-5472.CAN- 03-1941 14744774 (Pubitemid 38120899)
30. Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer. A Shah H Singh V Sachdev J Lee S Yotsukura R Salgia A Bharti, Current Proteomics 2010 7 49 56 10.2174/157016410790979635 20526421
31. The Clinical-Significance of the Serum Haptoglobin Concentration in Patients with Invasive Cervical-Carcinoma. EJ Neale WSF Wong M Arumanayagam MZA Chang, Aust N Z J Obstet Gynaecol 1989 29 197 199 10.1111/j.1479-828X.1989. tb01718.x 2604646 (Pubitemid 19217009)
32. Haptoglobin Expression in Endometrioid Adenocarcinoma of the Uterus. H Nabli E Tuller KL Sharpe-Timms, Reproductive Sciences 2010 17 47 55 10.1177/1933719109346331 19801537
33. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. E Weiderpass K Brismar R Bellocco H Vainio R Kaaks, Br J Cancer 2003 89 1697 1704 10.1038/sj.bjc.6601312 14583772 (Pubitemid 37464142)
34. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. S Hirano N Ito S Takahashi T Tamaya, Eur J Gynaecol Oncol 2004 25 187 191 15032278 (Pubitemid 38268694)
35. Genomics, proteomics and integrative 'omics' in hypertension research. [Miscellaneous Article]. V Thongboonkerd, Current Opinion in Nephrology & Hypertension 2005 14 133 139 (Pubitemid 40396866)
36. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. MM Bradford, Analytical Biochemistry 1976 72 248 254 10.1016/0003-2697(76)90527-3 942051
37. iTRAQ experimental design for plasma biomarker discovery. X Song J Bandow J Sherman JD Baker PW Brown MT McDowell MP Molloy, J Proteome Res 2008 7 2952 2958 10.1021/pr800072x 18549257